Is Stimulation of Prejunctional Dopamine Receptors an Antihypertensive Principle?

References

• Eble J. N. A proposed mechanism for the depressor effect of dopamine in the anaesthetized dog. J. Pharmacol. Exp. Ther. 1964; 145: 64–70
   PubMed Web of Science ®Google Scholar
• Clark B., Menninger K. Peripheral dopamine receptors. Circ. Res. 1980; 46: 1–59; 1–63
   PubMed Web of Science ®Google Scholar
• McNay J. L., MacCannell K. L., Meyer M. B., Goldberg L. I. Hypotensive effect of dopamine in dogs and hypertensive patients after phenoxybenzamine. J. Clin. Invest. 1966; 45: 1045–1046
   Web of Science ®Google Scholar
• Ventura H. O., Messerli F. H., Frohlich E. D., Kobrin I., Oigman W., Dunn F. G., Carey R. M. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 1984; 69: 1142–1145
   PubMed Web of Science ®Google Scholar
• Bucher T. J. Mechanism of the antihypertensive effect of bromocriptine in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 1982; 319: R62
   Google Scholar
• Lokhandwala M. F., Tadepalli A. S., Jandhyala B. S. Cardiovascular actions of bromocriptine: Evidence for a neurogenic mechanism. J. Pharmacol. Exp. Ther. 1979; 211: 620–625
   PubMed Web of Science ®Google Scholar
• Salzmann R., Unpublished results
   Google Scholar
• Ziegler M. G., Lake C. R., Williams A. C., Teychenne P. F., Shoulson I., Steinsland O. Bromocriptine inhibits norepinephrine release. Clin. Pharmacol. Ther. 1979; 25: 137–142
   PubMed Web of Science ®Google Scholar
• Ensinger H., Majewski H., Hedler L., Starke K. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits. J. Pharmacol. Exp. Ther. 1985; 234: 681–690
   PubMed Web of Science ®Google Scholar
• Hamed A. T., Lokhandwala M. F., Jandhyala B. S. Effect of bromocriptine on cardiac function and coronary blood flow. J. Cardiovasc. Pharmacol. 1981; 3: 636–646
   PubMed Web of Science ®Google Scholar
• Clark B. J. Dopamine receptors and the cardiovascular system. Postgrad. Med. J. 1981; 57: 45–54
   PubMed Web of Science ®Google Scholar
• De Jong W., Lambrechts A. C., van den Buuse M. Blood pressure effects of dopamine and bromocryptine in conscious spontaneously hypertensive rats (SHR). Br. J. Pharmacol. 1986; 89: 688P
   Google Scholar
• Volkman P. H., Goldberg L. I. Lack of correlation between inhibition of prolactin release and stimulation of dopaminergic renal vasodilation. Pharmacologist 1976; 18: 130
   Google Scholar
• Orzechowski R. F., Roby A. Effects of several central dopamine receptor stimulants on mesenteric arterial blood flow in anaesthetized dogs. Peripheral dopaminergic receptors, J.-L. Imbs, J. Schwartz. Pergamon Press, Oxford, New York 1979; 151–160
   Google Scholar
• Lang W. J., Woodman O. L. Comparison of the vasodilator action of dopamine and dopamine agonists in the renal and coronary beds of the dog. Br. J. Pharmac. 1982; 77: 23–28
   PubMed Web of Science ®Google Scholar
• Clark B. J., Unpublished results
   Google Scholar
• Woodman O. L., Rechtman M. P., Lang W. J. A comparison of the responses to some dopamine-receptor agonists and antagonists in the isolated perfused rat kidney. Arch int. Pharmacodyn. 1980; 248: 203–211
   PubMedGoogle Scholar
• Brodde O.-E., Freistühler J., Meyer F.-J. Stereospecific antagonism by d-butaclamol of dopamine-induced relaxation of the isolated rabbit mesenteric artery. J. Cardiovasc. Pharmacol. 1981; 3: 828–837
   PubMed Web of Science ®Google Scholar
• Oudart N., Sercombe R., Aubineau P., Boulu R. G., Seylaz J. Relaxation by dopaminergic agonists in cerebral and peripheral arteries (in vitro). Arch. int. Pharmacodyn. 1981; 252: 196–209
   PubMedGoogle Scholar
• Schmidt M., Imbs J. L., Giesen E. M., Schwartz J. Vasodilator effects of dopaminomimetics in the perfused rat kidney. Eur. J. Pharmacol. 1982; 84: 61–70
   PubMed Web of Science ®Google Scholar
• Loew D. M., van Deusen E. B., Meier-Ruge W. Effects on the central nervous system. Ergot alkaloids and related compounds, B. Berde, H. O. Schild. Springer-Verlag, Heidelberg 1978; 421–531, Handb. Exp. Pharmac. 49
   Google Scholar
• Clark B. J., Scholtysik G., Flückiger E. Cardiovascular actions of bromocriptine. Acta Endocr. 1978; 88(Suppl. 216)75–81
   PubMedGoogle Scholar
• Montastruc J.-L., Rascol A., Montastruc P. Etude expérimentale de l'action antihypertensive de la bromocriptine chez le chien. J. Pharmacol. (Paris) 1979; 10: 79–91
   Google Scholar
• Clark B. J. Cardiovascular effects of ergot alkaloids. J. Pharmacol. (Paris) 1979; 10: 439–453
   Google Scholar
• Lokhandwala M. F. Analysis of the effects of bromocriptine on blood pressure and sympathetic nerve function. Eur. J. Pharmacol. 1979; 56: 253–256
   PubMed Web of Science ®Google Scholar
• Scholtysik G. Dopamine receptor mediated inhibition by bromocriptine of accelerator nerve stimulation effects in the pithed cat. Br. J. Pharmacol. 1978; 62: 379P
   PubMed Web of Science ®Google Scholar
• Kao A., Kriett J. M., Tobler H. G., Detloff B. L. S., Pritzker M. R., Benson D. W., Benditt D. G. Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: Studies in a canine model. J. Amer. Coll. Cardiol. 1984; 4: 1188–1194
   PubMed Web of Science ®Google Scholar
• Falk R. H., Desilva R. D., Lown B. Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovasc. Res. 1981; 15: 175–180
   PubMed Web of Science ®Google Scholar
• Nilsson A., Hökfelt B. Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia. Acta Endocr. 1978; 88(Suppl. 216)83–96
   Google Scholar
• Dragatakis L. N., Küchel O., Larochelle P. Cardiovascular effects of bromocriptine in man. Clin. Pharmacol. Ther. 1980; 27: 250–251
   Web of Science ®Google Scholar
• Ziegler M. G., Kennedy B., Holland O. B., Murphy D., Lake C. R. The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems. Int. J. Clin. Pharmacol. Ther. Tox. 1985; 23: 175–179
   PubMed Web of Science ®Google Scholar
• Van Loon G. R., Sole M. J., Bain J., Ruse J. L. Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 1979; 28: 425–434
   PubMed Web of Science ®Google Scholar
• Whitfield L., Sowers J. R., Tuck M. L., Golub M. S. Dopaminergic control of plasma catecholamines and aldosterone responses to acute stimuli in normal man. J. Clin. Endocrinol. Metab. 1980; 51: 724–729
   PubMed Web of Science ®Google Scholar
• Carey R. M., van Loon G. R., Baines A. D., Kaiser D. L. Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J. Clin. Endocr. 1983; 56: 595–602
   PubMed Web of Science ®Google Scholar
• Sowers J. R., Golub M. S., Berger M. E., Whitfield L. A. Dopaminergic modulation of pressor and hormonal responses in essential hypertension. Hypertension 1982; 4: 424–430
   PubMed Web of Science ®Google Scholar
• Johns D. W., Ayers C. R., Carey R. M. The dopamine agonist bromocriptine induces hypotension by venous and arteriolar dilation. J. Cardiovasc. Pharmacol. 1984; 6: 582–587
   PubMed Web of Science ®Google Scholar
• Mannelli M., Delitala G., de Feo M. L., Maggi M., Cuomo S., Piazzini M., Guazzelli R., Serio M. Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. J. Clin. Endocrinol. Metab. 1984; 59: 74–78
   PubMed Web of Science ®Google Scholar
• Mercuro G., Rossetti Z. L., Tocco L., Rivano C. A., Cherchi A., Gessa G. L. Bromocriptine reduces plasma noradrenaline and 3,4-dihydrophenylacetic acid in normal and hypertensive subjects. Eur. J. Clin. Pharmacol. 1985; 27: 671–675
   PubMed Web of Science ®Google Scholar
• Steardo L., Di Stasio E., Bonuso S., Maj M. The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers. Eur. J. Clin. Pharmacol. 1986; 29: 713–715
   PubMed Web of Science ®Google Scholar
• Mohanty P. K., Sowers J. R., Beck F. W. J., Godschalk M. F., Schmitt J., Newton M., McNamara C., Verbalis J. G., McClanahan M. Catecholamine, renin, aldosterone and arginine vasopressin responses to lower body negative pressure and tilt in normal humans: Effects of bromocriptine. J. Cardiovasc. Pharmacol. 1985; 7: 1040–1047
   PubMed Web of Science ®Google Scholar
• Francis G. S., Goldsmith S. R., Cohn J. N. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive cardiac failure. Am. Heart J. 1982; 104: 725–731
   PubMed Web of Science ®Google Scholar
• Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 1984; 311: 819–823
   PubMed Web of Science ®Google Scholar
• Francis G. S., Parks R., Cohn J. N. The effects of bromocriptine in patients with congestive heart failure. Am. Heart J. 1983; 106: 100–106
   PubMed Web of Science ®Google Scholar
• Sowers J. R. Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension. J. Clin. Endocrinol. Metab. 1981; 53: 1133–1137
   PubMed Web of Science ®Google Scholar
• Kolloch R., Kobayashi K., DeQuattro V. Dopaminergic control of sympathetic tone and blood pressure: Evidence in primary hypertension. Hypertension 1980; 2: 390–394
   PubMed Web of Science ®Google Scholar
• Kolloch R. E., Stumpe K. O., Ismer U., Kletzky O., De Quattro V. Central dopaminergic mechanisms in young patients with essential hypertension. Clin. Sci. 1981; 61(Suppl. 7)231s–234s
   PubMed Web of Science ®Google Scholar
• Stumpe K. O., Kolloch R., Higuchi M., Krück F., Vetter H. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Lancet 1977; 2: 211–214
   PubMed Web of Science ®Google Scholar
• Hauger-Klevene J. H. Mechanisms of action of central antihypertensive drugs. BS-100/141 and bromoergocriptine in essential hypertension and active acromegaly: Effect on plasma renin activity, prolactin and pressor response to angiotensin II. Arterial hypertension, M. Velasco. Exerpta Medica, Amsterdam, Oxford-Princetown 1980; 262–271
   Google Scholar
• Gessa G. L., Mercuro G., Rossetti Z. L. Peripheral dopamine receptors controlling norepinephrine release in man. Modulation of Central and Peripheral Transmitter Function, G. Biggio, P. F. Spano, G. Toffano, G. L. Gessa. Fidia Research Series, II-Liviana Press, Padova 1986; 203–217, Symposia in Neuroscience
   Google Scholar
• Walden R. J., Hernandez J., Bhattacharjee P., Graham B., Prichard B. N. C. Bromocriptine in the treatment of hypertension. Eur. J. Clin. Pharmacol. 1986; 30: 141–144
   PubMed Web of Science ®Google Scholar
• Lewis M. J., Henderson A. H. The effects of bromocriptine in methyldopa treated hypertension. Br. J. clin. Pharmac. 1980; 9: 57–60
   PubMed Web of Science ®Google Scholar
• Schmidt M., Imbs J.-L. Effects rénaux de la bromocriptine. J. Pharmacol. (Paris) 1979; 10: 525–532
   Google Scholar
• Mahajan K. K., Manku M. S., Davidson H., James M. F., Robinson C. J., Horrobin D. F. Renal interactions of prolactin and bromocriptine. J. Endocr. 1976; 68: 14P
   PubMed Web of Science ®Google Scholar
• Richardson B., Luginbühl H. The role of prolactin in the development of chronic progressive nephropathy in the rat. Arch. A. Path. Anat. and Histol. 1976; 370: 13–19
   PubMed Web of Science ®Google Scholar
• Stier C. T., Cowden E. A., Allison M. E. M. Effects of bromocriptine on single nephron and whole-kidney function in rats. J. Pharmacol. Exp. Ther. 1982; 220: 366–370
   PubMed Web of Science ®Google Scholar
• Rothlin E. The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. Schweiz. Akad. med. Wiss. 1946; 2: 249–273
   Google Scholar
• Clark B. J., Bucher T., Waite R. Analysis of the cardiovascular effects of co-dergocrine (HydergineR). J. Pharmacol. (Paris) 1985; 16: 115–127, Suppl. III
   PubMedGoogle Scholar
• Memo M., Sagheddu G., Carruba M. O., Spano P. F. Dihydroergotoxine decreases blood pressure in spontaneously hypertensive rats by interacting with peripheral dopamine receptors. Life Sci. 1985; 36: 1515–1522
   PubMed Web of Science ®Google Scholar
• Picotti G. B., Bondiolotti G. P., Galva M. D., Cesura A. M., Spano P. F., Mantegazza P. Inhibition of peripheral noradrenaline release by DA2-dopamine receptor agonists in conscious spontaneously hypertensive rats. Modulation of Central and Peripheral Transmitter Function, G. Biggio, P. F. Spano, G. Toffano, G. L. Gessa. Fidia Research Series, III-Liviana Press, Padova 1986; 182–188, Symposia in Neuro-science
   Google Scholar
• Müller-Schweinitzer E. Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 1982; 318: 225–233
   Google Scholar
• Markstein R. Dopamine receptor profile of co-dergocrine (HydergineR) and its components. Eur. J. Pharmacol. 1983; 86: 145–155
   Web of Science ®Google Scholar
• Flückiger E., Del Pozo E. Ergot derivatives and pituitary hormones. Neuroactive Drugs in Endocrinology, E. E. Müller. Elsevier/North Holland Biomedical Press. 1980; 169–190
   Google Scholar
• Franceschini R., Marabini A., Cataldi A., Messina V., Salvemini M. Changes in serum prolactin and growth hormone values after dihydroergotoxine single-dose administration. IRCS Med. Sci. 1986; 14: 336
   Google Scholar
• Roquebert J., Demichel P. α-Adrenergic agonist and antagonist activity of dihydroergotoxine in rats. J. Pharm. Pharmacol. 1985; 37: 415–420
   PubMed Web of Science ®Google Scholar
• Siegl H. Renal and antihypertensive effects of co-dergocrine (HydergineR) in rats. J. Pharmacol. (Paris) 1985; 16: 129–144, Suppl. III
   PubMedGoogle Scholar
• Siegl H., unpublished results
   Google Scholar
• Blake W. D. Some effects of dihydrogenated ergot alkaloids on renal hemodynamics, water and electrolyte excretion in the dog. Amer. J. Physiol. 1953; 173: 337–344
   PubMed Web of Science ®Google Scholar
• Moyer J. H., Handley C. A., Seibert R. A. Effect of adrenergic blockade on renal hemodynamics and excretion of water and electrolytes. Amer. J. Physiol. 1955; 180: 146–150
   PubMed Web of Science ®Google Scholar
• Gerber A., Weidmann P., Laederach K. Cardiovascular regulation during administration of co-dergocrine to normal subjects. Eur. J. Pharmacol. 1986; 29: 565–572
   Web of Science ®Google Scholar
• Mercuro G., Rivano A. C., Ruscazio M., Tocco L., Cherchi A., Rossetti Z. L., Manca M. R., Franch F., Gessa G. L. Effects of long-term treatment with dihydroergotoxine (Hydergine R) on blood pressure and plasma norepinephrine in essential hypertensive patients. Modulation of Central and Peripheral Transmitter Function, G. Biggio, P. F. Spano, G. Toffano, G. L. Gessa. Fidia Research Series, III-Liviana Press, Padova 1986; 189–193, Symposia in Neuroscience
   Google Scholar
• Saborowski F. Co-dergocrinmesylat bei mittelschwerer bis schwerer Hypertonie im Alter. Münch, med. Wschr. 1985; 127: 529–531
   Google Scholar
• Krönig B., Dennler H.-J. Behandlung des älteren Hochdruck-kranken mit Co-dergocrinmesilat. Therapiewoche 1984; 34: 4887–4900
   Google Scholar
• Welzel D., Weidinger G., Koppenhagen K. Zentrale Hämodynamik der Antihypertensiva. Dtsch. med. Wschr. 1984; 109: 1064–1068
   PubMed Web of Science ®Google Scholar
• Kirsten R., Heintz B., Weidinger G., Welzel D. Stimulation präsynaptischer Dopaminrezeptoren als antihypertensives Prinzip. Herz-Kreisl. 1985; 17: 426–433
   Google Scholar
• Meurer K. A., Feltkamp H. Ueber die Behandlung des hohen Blutdrucks mit Hydergin spezial unter stationären Bedingungen. Medweilt 1984; 35: 698–701
   Google Scholar
• Kappert A. Die Behandlung der Hypertonie mit den Dihydroalkaloiden. Helv. Med. Acta 1949; 16: 127–163, Suppl. 22
   Google Scholar
• Kolloch R., Weidinger G., Welzel D., Stumpe K. O. Intra-venöse Applikation von Co-Dergocrinmesylat bei hypertensiver Krise: Ein Vergleich mit Clonidin. Herz-Kreisl. 1984; 16: 417–422
   Google Scholar
• Weth G. Clinical, endocrinological and biochemical effects of co-dergocrinmesylate in antihypertensive crisis in aged patients. Europ. Heart J. 1984; 5(Suppl. 1)333
   Google Scholar
• Weth G. Klinische und biochemische Wirkeffekte von Co-Dergocrinmesylat bei hypertensiver Krise. Müunch, med. Wschr. 1984; 126: 1186–1188
   Google Scholar
• Guffanti E., Vaccarella A., Meregalli M., Fiorella G., Chierichetti S. M., Mazzola C. A single blind comparison of dihydroergotoxine mesilate and clonidine for treatment of hypertensive emergencies. Int. J. Clin. Pharmacol. Ther. Toxicol. 1985; 23: 506–509
   PubMed Web of Science ®Google Scholar
• McCall M. L., Taylor H. W. The action of hydergine on the circulation and metabolism of the brain in toxemia of pregnancy. Am. J. Med. Sci. 1953; 226: 537–540
   PubMed Web of Science ®Google Scholar
• Barcroft H., Konzett H., Swan H. J. C. Observations on the action of the hydrogenated alkaloids of the ergotoxine group on the circulation in man. J. Physiol. 1951; 112: 273–291
   PubMed Web of Science ®Google Scholar
• Hoobler S. W., Dontas A. S. Drug treatment of hypertension. Pharmacol. Rev. 1953; 5: 135–174
   PubMed Web of Science ®Google Scholar